Correcting tyrosinaemia via a point mutation
Crossref DOI link: https://doi.org/10.1038/s41551-019-0489-x
Published Online: 2020-01-14
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Musunuru, Kiran http://orcid.org/0000-0003-3298-0368
Text and Data Mining valid from 2020-01-14
Version of Record valid from 2020-01-14
Article History
First Online: 14 January 2020
Competing interests
: K. M. is a co-founder and advisor of Verve Therapeutics, and an advisor of Variant Bio.